Securities code: 002382 securities abbreviation: Blue Sail Medical Co.Ltd(002382) Announcement No.: 2021-004 bond Code: 128108 bond abbreviation: lanfan convertible bond
Blue Sail Medical Co.Ltd(002382)
Announcement on resolutions of the 19th meeting of the 5th board of supervisors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
The 19th meeting of the 5th board of supervisors of Blue Sail Medical Co.Ltd(002382) (hereinafter referred to as “the company” or ” Blue Sail Medical Co.Ltd(002382) “) was notified by e-mail on January 10, 2022 and held on site in the second conference room of the company on January 13, 2022. There were 3 supervisors who should attend the meeting and 3 actually attended the meeting. Mr. Zhu Jianhong, chairman of the board of supervisors, presided over the meeting. The meeting was held in accordance with the company law of the people’s Republic of China and the Blue Sail Medical Co.Ltd(002382) articles of association.
2、 Deliberation at the meeting of the board of supervisors
1. Deliberated and passed the proposal on cooperative investment funds between subsidiaries and professional investment institutions;
It is agreed that the company’s subsidiary Shandong Jiwei Medical Products Co., Ltd. (hereinafter referred to as “Jiwei medical”) and China-Singapore Suzhou Industrial Park Development Group Co.Ltd(601512) and other limited partners participate in the investment of Suzhou Industrial Park Yisheng phase I venture capital partnership (limited partnership) (hereinafter referred to as “Yisheng phase I”) initiated and established by Suzhou Industrial Park Yisheng Private Fund Management Co., Ltd, The target fund size is RMB 300 million. Among them, Jiwei medical, as a limited partner, contributed RMB 20 million with its own funds.
Yisheng phase I, based on the high-quality and rich project resources in the Yangtze River Delta accumulated by the Oriental medical device innovation center and the China cardiovascular doctor Innovation Club (CCI), and relying on the operation strength of the head industry, University, research and medicine and the industrial park, invests in early-stage medical devices, in vitro diagnostic reagents, stem cells, biotechnology and medical services, which is conducive to the company’s layout of great health The industry and investment in the new medical field are in line with the company’s strategic development plan.
The board of supervisors believes that Gewei medical’s participation in the investment of Yisheng phase I fund will not affect the normal production and operation activities of the company and its subsidiaries, will not have a significant impact on the financial status and operating results of the company and its subsidiaries, and will not damage the interests of minority shareholders.
Voting results: 3 in favor, 0 against and 0 abstention.
See China Securities Journal, Shanghai Securities News, securities times, securities daily and cninfo.com, the information disclosure media designated by the company, for details of the announcement on cooperative investment funds between subsidiaries and professional investment institutions（ http://www.cn.info.com.cn. ）。
2. The proposal on the proposed internal asset restructuring was reviewed and adopted.
Agree to transfer part of the company’s assets and liabilities related to the production and operation of health protection gloves business as of the base date December 31, 2021 to Zibo lanfan new materials Co., Ltd. (hereinafter referred to as “Zibo new materials”) based on the estimated net book value of 1250393200 yuan (Unaudited) Zibo lanfan Health Technology Co., Ltd. (hereinafter referred to as “Zibo health technology”), of which the net book value transferred to Zibo new materials is 488631000 yuan and the net book value transferred to Zibo health technology is 761762200 yuan. This transfer will transfer the personnel related to the transfer business to Zibo new materials and Zibo health technology in accordance with the principle of “people follow the business and assets”.
The board of supervisors believes that the internal assets reorganization is carried out within the scope of the company’s consolidated statements, does not involve changes in the scope of the consolidated statements, will not have a significant impact on the company’s financial status and operating results, and there is no situation that damages the interests of the company and shareholders.
Voting results: 3 in favor, 0 against and 0 abstention.
See China Securities News, Shanghai Securities News, securities times, securities daily and cninfo.com, the information disclosure media designated by the company, for details of the announcement on the proposed internal asset restructuring（ http://www.cn.info.co m.c n）。 3、 Documents for future reference
Resolution of the 19th meeting of the 5th board of supervisors of the company.
It is hereby announced.
Blue Sail Medical Co.Ltd(002382)
Board of supervisors
January 14, 2002
